The effect of an a-2 receptor antagonist, ida zoxan, on ischemic neuronal damage in the hippocampus and neocortex was studied in rats following 10 min of forebrain ischemia. Idazoxan was given 0. 1 mg/kg i. v. immediately after recirculation, followed by 48 h of con tinuous infusion at a rate of 10 fLg/kg/min. A histopatho logical examination of the CAl region of the dorsal hip pocampus and neocortex from each hemisphere was made on paraffin-embedded sections following 7 days of survival. In ischemic animals receiving an infusion of sa-Neurotransmitters have become increasingly rec ognized as important factors in the development of neuronal damage following ischemia and hypogly cemia (Wieloch, 1985; Rothman and Olney, 1986) . Several lines of evidence indicate a protective in fluence of neurotransmitters and neuromodulators in the rodent brain (Wieloch, 1985) , including those involved in the ascending noradrenergic fibre sys tem originating in the locus coeruleus (Blomqvist et aI., 1985). In the present study on rats we demon strate protection against neuoronal damage follow ing ischemia by idazoxan (2-[2-(1,4-benzo dioxanyl)]-2-imidazoline Hel), a potent and selec tive a-2 receptor antagonist, and an activator of the locus coeruleus noradrenergic neurons, and we pro pose that this class of drugs may be beneficial in the treatment of ischemic brain damage.
Summary:
The effect of an a-2 receptor antagonist, ida zoxan, on ischemic neuronal damage in the hippocampus and neocortex was studied in rats following 10 min of forebrain ischemia. Idazoxan was given 0. 1 mg/kg i. v. immediately after recirculation, followed by 48 h of con tinuous infusion at a rate of 10 fLg/kg/min. A histopatho logical examination of the CAl region of the dorsal hip pocampus and neocortex from each hemisphere was made on paraffin-embedded sections following 7 days of survival. In ischemic animals receiving an infusion of sa-Neurotransmitters have become increasingly rec ognized as important factors in the development of neuronal damage following ischemia and hypogly cemia (Wieloch, 1985; Rothman and Olney, 1986) . Several lines of evidence indicate a protective in fluence of neurotransmitters and neuromodulators in the rodent brain (Wieloch, 1985) , including those involved in the ascending noradrenergic fibre sys tem originating in the locus coeruleus (Blomqvist et aI., 1985) . In the present study on rats we demon strate protection against neuoronal damage follow ing ischemia by idazoxan (2-[2-(1,4-benzo dioxanyl)]-2-imidazoline Hel), a potent and selec tive a-2 receptor antagonist, and an activator of the locus coeruleus noradrenergic neurons, and we pro pose that this class of drugs may be beneficial in the treatment of ischemic brain damage.
MATERIALS AND METHODS
Male Wistar rats weighing between 270 and 390 g were used for the experiments. They were fasted overnight preceding the operation but had free access to tap water. line, 71% of the neurons in the hippocampal CAl region were degenerated. In contrast, in the idazoxan-treated animals only 31 % of the neurons were irreversibly dam aged (p < 0.01). We conclude that postischemic admin istration of the a-2 antagonist idazoxan protects neurons against damage following cerebral ischemia. Rapid post ischemic administration of a-2 adrenergic receptor antag onists could be an effective treatment after stroke and cardiac arrest. Key Words: Ischemia-Neuronal dam age-a-Adrenergic drugs-Idazoxan.
Following anaesthetic induction with 3-4% isoflurane in a 70% N20/02 mixture the rats were endotracheally intubated (Intramedic PE 240) and connected to a Star ling-type respirator. Anaesthesia was maintained with isoflurane 1.5% in N20/02• Through a neck incision both common carotid arteries were exposed and prepared for later occlusion. A silicone catheter (ID 0. 03 in. , OD 0. 05 in. ) was inserted into the right external jugular vein and advanced 4-5 cm to reach a position suited for rapid with drawal of blood later in the procedure. The tail artery was cannulated for continuous monitoring of blood pressure and for intermittent sampling of arterial blood. A tail vein was cannulated to allow intravenous injection of drugs. A pair of needle electrodes were inserted through small skin incisions into the temporalis muscle to obtain an inter hemispheric EEG during the ischemia period. Ther mistors were placed on the skull surface and in the rectum to control the temperature. Following the operating pro cedures, the rats were allowed a 30-min stabilization pe riod with isoflurane reduced to 1 %, while the rectal and skull temperatures were kept at close to 37°C and the arterial blood gases within normal limits. Heparin 50 IV was given intravenously as an anticoagulant. Cerebral ischemia was induced and maintained for 10 min by a combination of bilateral carotid clamping and reduction of arterial blood pressure. The procedure is a modifica tion of a method described earlier from this laboratory (Smith et aI. , 1984) , omitting the use of a muscle relaxant and trimetaphan while maintaining the inhalation anaes thetic agent isoflurane. Isoflurane was discontinued I min before induction of ischemia while ventilation with N20 was going on. Immediately before the ischemia, blood was withdrawn through the silicone catheter to reach a MABP of about 70 mm Hg. Both carotid arteries were clamped, and blood was then further withdrawn, and if necessary reinfused, to reach and maintain a stable MABP of 50 mm Hg throughout the ischemia period. The onset of cerebral ischemia was defined as the time of cessation of EEG activity, usually within I min after clamping. At the end of the ischemia period, the vascular clamps were removed and the withdrawn blood was re infused. Sodium bicarbonate (0. 5 ml of a 0. 6 M solution) was given intravenously. The jugular vein catheter was removed and replaced by a polyethylene catheter (Portex PE 50) which was advanced 3 cm into the superior vena cava. The outer end of the catheter was tunneled to an exit point in the dorsal neck and connected to a syringe with a mechanical pump. A swivel connector (Carnegie Medicin AB, Stockholm, Sweden) was used together with a metal spring between the animal and the syringe in or der to prevent twisting and kinking of the catheter. The spring was attached with sutures to the skin of the rat, allowing free movements later in the cage without dis turbing the intravenous drug infusion.
During the immediate recovery period after the opera tion, the blood pressure monitoring continued, the arte rial P02, PC02, and pH values were checked and the animals were allowed to regain consciousness and spon taneous respiration. Extubation was feasible 15-20 min after the end of ischemia, and the rats were then trans ferred to special circular cages with a diameter of about 25 cm and a hole for the infusion device in the lid of the cage. The spring connection did not affect the postisch emic behavior of the animal.
Twenty rats were divided into two groups. In the ex periment group, 10 rats were given idazoxan 0.1 mg/kg i. v. immediately after the end of ischemia. The injection was subsequently followed by an infusion of idazoxan ( I mg/m!) at a rate of 10 jl.g/kg/min for 48 h. Ten rats given the same volumes of saline served as controls. Idazoxan was kindly provided by Dr. J. Doxey (Reckitt and Col man, Kingston-Upton-Hill, UK).
The histological studies were done on animals with a survival time of 7 days after the ischemic insult. Then the rats were anesthetized with halothane, tracheostomized, and connected to a respirator. The brains were perfusion fixed in vivo via the ascending aorta with a 4% formalde hyde solution buffered to a pH of 7. 35, preceded by a short saline rinsing. Both solutions were prewarmed to 3rc. The brains were removed and subsequently stored in cold formaldehyde solution until further processed.
The preparation and staining of the brain sections with celestine blue-acid fuchsin have been described in detail elsewhere (Wieloch, 1985) . Sectioning intervals were adapted to obtain standard levels of the caudate nucleus, cortex, and hippocampus throughout its extent. The quantification of hippocampal injury was done in the dor sal hippocampal region approximately 3.8 mm caudally from bregma (according to Paxinos and Watson, 1982) . Cortical areas were examined throughout the brain sec tions, as the cellular necrosis was much less extensive than in the hippocampus and unevenly distributed. The most damaged area, which was usually found temporally, was used for cell counting. With the staining procedure adopted, the necrotic neurons appear bright red on ex amination under the light microscope, and the extent of injury is expressed as percentage necrotic neurons of the total number in each area examined at a magnification of x40.
The data were analyzed using a two sample rank-sum test. Figure I shows light microscopy pictures of the CAl region of the dorsal hippocampus from (a) a nonischemic (normal) animal, (b) a control animal which received saline following a period of 10 min of ischemia, and (c) an animal given idazoxan after ischemia. In the normal animal, the neurons appear round with prominent nuclei and nucleoli. In the saline-treated ischemic controls � 70% of the neu rons were necrotic, shrunken, and triangular shaped with a condensed nucleus. In the neuropil, extensive infiltration of macrophages is evident. In the idazoxan-treated animals, a marked reduction of necrotic neurons is seen. The neuronal cell counts in the idazoxan-treated and nontreated groups expressed as percent dead or dying (acido- FIG. 1. Photomicrograph of the CA 1 region of the dorsal hippocampus of a normal (nonischemic) rat (a), a control rat subjected to 10 min of ischemia and one week survival given an infusion of saline (b), and a rat subjected to 10 min of ischemia and 1 week survival treated with idazoxan immediately following recirculation (e). Bars = 100 fJ.m. philic) cells out of the total number of cells in the CAl area of the dorsal hippocampus and in neo cortex is shown in Fig. 2 . The values of the individ ual animals are also indicated. Forty-eight hours of infusion of idazoxan decreased the neuronal necro sis in the CA 1 area of the dorsal hippocampus sig nificantly by more than 50% from 71 to 31% (p < 0.01). Similarly, in the most damaged area of the neocortex, the necrosis decreased from 7 to 1 % (p < 0.01). In two animals out of the ten treated, no protective effect was noticed.
RESULTS AND DISCUSSION
Our results demonstrate a significant protective effect of idazoxan, an u-2 antagonist, against isch emic brain damage in the rat. The results support the view that noradrenaline is a protective transmit ter in the CN S (Blomqvist et aI., 1985; Wieloch, 1985; Koide et aI., 1986; Wieloch et aI., 1986; Ne vander et aI., 1986) and that sustained stimulation of the postischemic cerebral noradrenaline release is beneficial for the recovery of the brain following an ischemic insult. The importance of the noradrener gic locus coeruleus system as a protective system against brain damage has been recognized during recent years. Depletion of noradrenaline in the brain lowers the threshold for induction of seizures (Mason and Corcoran, 1979) . Lesions of the LC was shown to increase the neuronal damage due to sustained epileptic seizures (Nevander et aI., 1986) . Similarly, selective lesions of the LC by local bilat eral injections of 6-hydroxydopamine (6-0HDA) into the dorsal bundle in the caudal mesencephalon increased neuronal damage following cardiac arrest ischemia (Blomqvist et aI., 1985) . Pharmacological depletion of noradrenaline by u-methyl-p-tyrosine, an inhibitor of tyrosine hydroxylase, given 24 h be fore ischemia, decreased the noradrenaline levels in the brain by 75% and, concomitantly, increased the cell damage in the CAl region from 24 to 95% and in the caudate nucleus from 0 to 60% (Wieloch et aI., 1986 ). The LC system probably is activated in the recovery period following ischemia. For example, the turnover ofNA in cortex is enhanced during the first 30-60 min of recirculation following two vessel occlusion ischemia (Calderini et aI., 1978) . The protective effect of idazoxan in the present study could be due to an enhanced and/or prolonged release of NA in the cortical areas studied, by blockade of the u-2 receptor-mediated recurrent in hibition of the NA-containing LC neurons (Aghaja nian, et aI., 1977) . This hypothesis is supported by the finding that systematic administration of the u-2 receptor antagonist yohimbine increases the extra cellular concentration of NA in the dorsal hippo campal area to more than twice the basal value in awake and freely moving rats (Abercrombie et aI., 1987) , as studied with a microdialysis technique. A marked increase in cortical noradrenaline release after intraperitoneal administration of idazoxan has also been reported (L'Heureux et aI., 1986) .
The cellular effects of a presumed increased post ischemic cortical NA release, induced by idazoxan, is complex. An increased release of NA may acti vate several different classes of receptors that may have either excitatory (McCormick and Prince, 1988; Madison and Nicoll, 1986) or inhibitory ef fects (Segal and Bloom, 1976; Mason and Corcoran, 1979; Woodward et aI., 1979; Pang and Rose, 1987) . Furthermore, the effects of ischemia on the density and characteristics of the adrenergic receptors, and on the responses of the second messenger systems to receptor stimulation, are unknown. At this stage, a discussion on the detailed receptor-mediated mechanisms would thus be premature.
Although we are inclined to favor a direct protec tive action of NA on the vulnerable neurons, other mechanisms must also be considered, such as ef- fects on peripheral tissue (Elliott et aI., 1984; Brown et aI., 1985; Struthers et aI., 1985) . The effects of changes in blood corticosteroid and NA levels on cell damage following ischemia (Sapoisky and Pulsinelli, 1985; Koide et aI., 1986 ) could be another potential modulatory mechanism.
In conclusion, we have demonstrated a cerebral protective effect of a-2 receptor antagonist, devoid of significant adverse effects on humans, that might be of potential clinical significance in the treatment of stroke and as a part of intensive care following cardiac arrest.
